Co-crystal of tramadol–celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase II trial
Author
López-Cedrún, José
Videla, Sebastián
Burgueño, Miguel
Juárez, Inma
Martín-Granizo, Rafael
Grau, Joan
Puche, Miguel
Gil-Diez, José-Luis
Hueto Madrid, Juan Antonio
vaqué, anna
Sust, Mariano
Plata-Salamán, Carlos
Monner, Antoni
Co-Crystal of Tramadol-Celecoxib Team
Publication date
2018ISSN
1174-5886
Abstract
Background: Co-crystal of tramadol–celecoxib (CTC), containing equimolar quantities of the active pharmaceutical ingredients (APIs) tramadol and celecoxib (100 mg CTC = 44 mg rac–tramadol hydrochloride and 56 mg celecoxib), is a novel API-API co-crystal for the treatment of pain. We aimed to establish the effective dose of CTC for treating acute pain following oral surgery. Methods: A dose-finding, double-blind, randomised, placebo- and active-controlled, multicentre (nine Spanish hospitals), phase II study (EudraCT number: 2011-002778-21) was performed in male and female patients aged ≥ 18 years experiencing moderate to severe pain following extraction of two or more impacted third molars requiring bone removal. Eligible patients were randomised via a computer-generated list to receive one of six single-dose treatments (CTC 50, 100, 150, 200 mg; tramadol 100 mg; and placebo). The primary efficacy endpoint was the sum of pain intensity difference (SPID) over 8 h assessed in the per-protocol population. Results: Between 10 February 2012 and 13 February 2013, 334 patients were randomised and received study treatment: 50 mg (n = 55), 100 mg (n = 53), 150 mg (n = 57), or 200 mg (n = 57) of CTC, 100 mg tramadol (n = 58), or placebo (n = 54). CTC 100, 150, and 200 mg showed significantly higher efficacy compared with placebo and/or tramadol in all measures: SPID (0–8 h) (mean [standard deviation]): − 90 (234), − 139 (227), − 173 (224), 71 (213), and 22 (228), respectively. The proportion of patients experiencing treatment-emergent adverse events was lower in the 50 (12.7% [n = 7]), 100 (11.3% [n = 6]), and 150 (15.8% [n = 9]) mg CTC groups, and similar in the 200 mg (29.8% [n = 17]) CTC group, compared with the tramadol group (29.3% [n = 17]), with nausea, dizziness, and vomiting the most frequent events. Conclusion: Significant improvement in the benefit–risk ratio was observed for CTC (doses ≥ 100 mg) over tramadol and placebo in the treatment of acute pain following oral surgery.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
616.3 - Pathology of the digestive system. Complaints of the alimentary canal
Keywords
Dolor oral postquirúrgic
Tractament del dolor
Cirurgia oral
Dolor oral postquirúrgico
Tratamiento del dolor
Cirugía oral
Postoperative oral pain
Pain treatment
Oral surgery
Pages
12
Publisher
Springer Nature
Collection
18;
Is part of
Drugs in R&D
Citation
López-Cedrún, José; Videla, Sebastián; Burgueño, Miguel [et al.]. Co-crystal of tramadol–celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase II trial. Drugs in R&D, 2018, 18, p. 137–148. Disponible en: <https://link.springer.com/article/10.1007%2Fs40268-018-0235-y>. Fecha de acceso: 19 ene. 2022. DOI: 10.1007/s40268-018-0235-y
This item appears in the following Collection(s)
- Odontologia [228]
Rights
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/